SCHEMBL992668

SCHEMBL992668

CCCCCCCCCCCCCCCC(N)=S

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 1/20 0.56
SPHK1 Q9NYA1 1/20 0.56
CES2 O00748 3/20 0.48
CES1 P23141 3/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
FAAH O00519 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
SOAT1 P35610 1/20 0.46
GPR84 Q9NQS5 7/20 0.46
PPARG P37231 7/20 0.46
PPARD Q03181 7/20 0.46
PPARA Q07869 7/20 0.46
HDAC11 Q96DB2 5/20 0.46
TSHR P16473 5/20 0.46
PTPN1 P18031 3/20 0.46
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11017002 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL3661831 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL7640632 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL6836310 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL3033182 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL7504525 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL2531077 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL1312624 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL10704488 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1
SCHEMBL9629897 1.00 SPHK2 (0.56) SPHK2SPHK1CES2CES1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3024036-B1 MANUFACTURING METHOD FOR CI(G)S NANOPARTICLES FOR MANUFACTURING LIGHT-ABSORBING LAYER, AND CI(G)S NANOPARTICLES MANUFACTURED USING SAME LG CHEMICAL LTD (KR) 2018-09-05 EP claimed
EP-0035208-B1 METHOD OF MAKING VISIBLE STATIONARY HEAT TRANSFER COEFFICIENT FIELDS BY PHOTOCHEMICAL MEANS SIEMENS AKTIENGESELLSCHAFT (DE) 1985-05-29 EP claimed
US-20240043808-A1 Screenable Liver Disease Models and Methods INSPHERO AG (CH) 2024-02-08 US disclosed
WO-2023091173-A1 METHODS OF LIVER DISEASE TREATMENT HUDNALL MICHAEL (US) 2023-05-25 WO disclosed
WO-2022115488-A1 IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2022-06-02 WO disclosed
US-11252984-B2 Methods of liver disease treatment HEPASSURE, INC. 2022-02-22 US disclosed
US-20200332300-A1 MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS AADIGEN, LLC 2020-10-22 US disclosed
EP-3559212-A1 SCREENABLE LIVER DISEASE MODELS AND METHODS Insphero AG (CH) 2019-10-30 EP disclosed
US-20190316093-A1 SCREENABLE LIVER DISEASE MODELS AND METHODS INSPHERO AG (CH) 2019-10-17 US disclosed
EP-3424511-A1 MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS Aadigen, LLC (US) 2019-01-09 EP disclosed
US-20180187199-A1 MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS AADIGEN LLC (US) 2018-07-05 US disclosed
CN-1835889-A Process for producing hydroxylamine SHOWA DENKO KK (JP) 2006-09-20 CN disclosed
WO-2006062178-A2 STABILIZER FOR HYDROXYLAMINE, METHOD FOR STABILIZING HYDROXYLAMINE, AND STABILIZED HYDROXYLAMINE SOLUTION SHOWA DENKO K.K. (JP) 2006-06-15 WO disclosed
EP-1663862-A2 PROCESS FOR PRODUCING HYDROXYLAMINE Showa Denko K.K. (JP) 2006-06-07 EP disclosed
WO-2005016817-A2 PROCESS FOR PRODUCING HYDROXYLAMINE SHOWA DENKO K. K. (JP) 2005-02-24 WO disclosed
EP-1296714-A2 METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2003-04-02 EP disclosed
US-20030026801-A1 Methods for enhancing antibody-induced cell lysis and treating cancer PFIZER INC. 2003-02-06 US disclosed
US-20020156033-A1 Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer COLEY PHARMACEUTICAL GROUP, INC. 2002-10-24 US disclosed
WO-2001097843-A2 METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2001-12-27 WO disclosed
US-3948892-A 2-Alkoxy(and 2-amino)-3-amino-2-heterocyclic-thiopropanamides SMITHKLINE CORPORATION (US) 1976-04-06 US disclosed